Results 161 to 170 of about 114,831 (298)

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) and cannabigerol (CBG) alleviate hepatic steatosis in obese mice by shifting energy buffering towards phosphocreatine and enhancing lysosomal lipid degradation and trafficking. These effects are associated with increased creatine kinase activity and lysobisphosphatidic acid (LBPA) levels, highlighting a previously unrecognised ...
Radka Kočvarová   +12 more
wiley   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena   +5 more
wiley   +1 more source

Circulating Cathepsin D Exacerbates Injury-Induced Brain Damage by Promoting Neutrophil Infiltration Into the Brain. [PDF]

open access: yesJ Am Heart Assoc
Liang Y   +15 more
europepmc   +1 more source

Enhanced Osteocyte Differentiation: Cathepsin D and L Secretion by Human Adipose-Derived Mesenchymal Stem Cells. [PDF]

open access: yesCells, 2023
Choi JW   +9 more
europepmc   +1 more source

Phagocyte proteinases in multiple trauma and sepsis [PDF]

open access: yes, 1993
Fritz, Hans   +4 more
core   +1 more source

Autophagy Inhibition by Fangji Huangqi Decoction Enhances Tumor Immunogenicity and Potentiates PD‐1 Blockade

open access: yesCancer Science, EarlyView.
In tumor cells, MHC‐I is typically degraded through autophagy, leading to reduced antigen presentation. However, Fangji Huangqi Decoction (FJHQ), acting as an autophagy inhibitor, suppresses lysosomal acidification, which in turn inhibits the degradation of MHC‐I. This results in increased surface expression of MHC‐I on tumor cells.
Yuxiao Jiang   +18 more
wiley   +1 more source

The Diagnostic Odyssey of a Biochemically Confirmed Case of ML II: The First Western Patient With LYSET Deficiency

open access: yesClinical Genetics, EarlyView.
We identify a female patient with a homozygous nonsense variant (p.Gln38Ter) in the LYSET gene. This is the first western report of a challenging case of an extensive diagnostic odyssey and demonstrates that the LYSET gene must be considered in the differential diagnosis when M6P‐labeled lysosomal enzymes are altered.
Fernanda Sperb‐Ludwig   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy